NASDAQ-GM · traded in Congress
Ligand Pharmaceuticals LGND
$306.20 +7.20 (+2.41%) Nov 6, 2026
Market value$6.1B
P/E ratio-
Analyst target$350.00
52-week range-
Avg volume236,290
Dividend yieldN/A
Chart
Analyst ratings
- 11 buy
- 0 hold
- 0 sell
Low target$335.00
Average target$360.82
High target$406.00
Quarterly financials
| Quarter ended | Revenue | Gross profit | Net income | Net margin |
|---|---|---|---|---|
| $79M | - | $-28M | -36.2% | |
| $64M | - | $49M | 76.2% | |
| $52M | - | $-13M | -25.8% | |
| $60M | - | $45M | 75.1% |
Congress trades in LGND
Members of Congress disclosed 2 transactions in LGND in the filings we have processed.
| Traded | Member | Type | Amount | Filed |
|---|---|---|---|---|
| 05/29/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 6/8/2026 filing |
| 03/03/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 4/7/2026 filing |
Disclosed under the STOCK Act. Amounts are the ranges the law requires, filings can lag a trade by up to 45 days, and a disclosure is not evidence of wrongdoing. All congressional trades ›
Other companies
Price and key figures from Nasdaq's public quote data, refreshed through the day; the chart is live from TradingView; options activity, ratings, financials, earnings and filings refreshed through the day. Congressional trades parsed from official House filings. Market information, not investment advice.
